Current perspectives: iron management during therapy with recombinant human erythropoietin.
Recombinant human erythropoietin (rHuEpo) has been associated with clinical and symptomatic improvements as well as improvements in quality of life in patients with anemia of chronic renal failure. However, resistance to rHuEpo therapy, related to insufficient iron stores, occurs often. Although many patients treated with rHuEpo take oral iron, patients continue to develop iron deficiency. Parenteral iron is a safe and effective alternative in replacing iron stores to sustain erythropoiesis in patients treated with rHuEpo.
York
S
S
D000747:Anemia, Hypochromic / Q000517:prevention & control*; D004351:Drug Resistance; D004509:Education, Nursing, Continuing; D004921:Erythropoietin / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000008:administration & dosage* / Q000097:blood; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy*; D010353:Patient Education as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron